Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01121562
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
🇯🇵Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01118351
- Locations
- 🇺🇸
CCF-Fairview Hospital, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Hospital del Mar
- Target Recruit Count
- 41
- Registration Number
- NCT01118039
- Locations
- 🇪🇸
Hospital Universitario San Carlos, Madrid, Spain
🇪🇸Hospital Del Mar, Barcelona, Spain
🇪🇸Hospital de la Santa Cruz i Sant Pau, Barcelona, Spain
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Duke University
- Target Recruit Count
- 131
- Registration Number
- NCT01108445
- Locations
- 🇬🇧
The Royal Marsden NHS, London, England, United Kingdom
🇬🇧Weston Park Hospital, Sheffield, England, United Kingdom
🇺🇸Duke Univeristy Medical Center, Durham, North Carolina, United States
Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2013-03-11
- Lead Sponsor
- Grupo Español de Investigación en Neurooncología
- Target Recruit Count
- 12
- Registration Number
- NCT01100177
- Locations
- 🇪🇸
Grupo Español de Investigacion en Neurooncologia, Madrid, Spain
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
- Conditions
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 63
- Registration Number
- NCT01089088
- Locations
- 🇬🇧
Royal Shrewsbury Hospital, Shrewsbury, Shropshire, United Kingdom
🇬🇧Royal Bournemouth Hospital, Bournemouth, England, United Kingdom
🇬🇧The Royal Marsden Hospitals (Surrey), Sutton, Surrey, United Kingdom
Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT01082809
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2013-07-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT01073644
- Locations
- 🇵🇭
Chong Hua Hospital, Cebu City, Philippines
🇵🇭Private Clinic, Manila, Philippines
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT01070186
Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
- Conditions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Korean Urological Oncology Society
- Target Recruit Count
- 32
- Registration Number
- NCT01069770
- Locations
- 🇰🇷
Chungbuk University Hospital, Cheonju, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.